Add-on nauseam: Change epilepsy drugs vocabulary, pleads Briviact researcher
The principal investigator for the original proof-of-concept study with just-approved epilepsy drug Briviact (brivaracetam) told BioWorld Today she's campaigning to get the FDA to cut the "add-on" description for such therapies, because there is "no indication that a drug that works as an add-on would not work by itself," and the tag is confusing to everyone including payers.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST